After graduation from the University of Graz in 1985 Dr. Windisch spent several years heading a neurobiology group at the University with research in the field of brain metabolism and animal model development after which he was involved for many years in University and industrial research programs in Europe, North America and Asia.

He stablished a global network of research collaborations and stimulated intensive scientific information exchange. Besides his involvement in research on neurotrophic and neuroprotective factors, he spearheaded several international clinical studies in Alzheimer’s disease, vascular dementia and ischemic stroke from 1989 onwards.

While founding his first CRO, JSW-Lifesciences 1999, the research activities were concentrated on the role of alpha and beta-synuclein in pathogenesis of PD and AD, to explore new therapeutic possibilities.

Going on to create and standardize improved transgenic and induced rodent models of neurodegenerative diseases.

Dr. Windisch gained enormous experience in use of such models and was involved every year in about 60-80 pharmacological studies in the field of neuro-degeneration, allowing him defining experimental standards to increase the predictive value in preclinical drug testing.

There is practically no class of compounds which was not investigated in these systems.